Market revenue in 2023 | USD 459.5 million |
Market revenue in 2030 | USD 1,622.4 million |
Growth rate | 19.7% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Banks |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Tools, Banks, Services |
Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regenerative medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 76.78% in 2023. Horizon Databook has segmented the Sweden regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
The competition in the Swedish market for regenerative medicine is anticipated to grow over the forecast period due to increasing investments in ATMPs and increasing focus on cell & gene therapies. The government is providing funding and investment to boost the market growth. Thus, such strategies undertaken by the government to strengthen the ATMPs are anticipated to boost the competition for regenerative medicine.
Moreover, increasing clinical trials and approvals for clinical trials of gene & cell therapies in the country are expected to increase the market rivalry. For instance, in October 2022, a clinical study for stem cell-based therapy to treat Parkinson’s disease was approved by the Swedish Medical Products Agency (MPA). Luxturna, a gene therapy for inherited retinal degeneration, was also approved in Sweden. In addition, Yescarta and Zolgensma are available for patients in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden regenerative medicine market , including forecasts for subscribers. This country databook contains high-level insights into Sweden regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account